Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.61 0.87 (0.99%) as of 4:30 Wed 3/27


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.69(B)
Last Volume: 1,031,697 Avg Vol: 1,398,626
52 Week Range: $76.22 - $100.3
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:

    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 92,341 116,105 269,465 610,463
Total Sell Value $8,237,699 $10,489,308 $24,880,826 $57,517,351
Total People Sold 3 4 5 8
Total Sell Transactions 9 11 22 59
End Date 2023-12-28 2023-09-26 2023-03-28 2022-03-28

   
Records found: 1303
  Page 10 of 53  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-14 4 S $70.17 $1,052,492 I/I (15,000) 20,609     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-14 4 OE $12.99 $194,850 I/I 15,000 35,609     -
   Mueller Brian VP, Corporate Controller   •       –      –    2013-05-14 4 S $70.33 $348,045 D/D (4,947) 6,660     -
   Mueller Brian VP, Corporate Controller   •       –      –    2013-05-14 4 OE $21.51 $75,285 D/D 3,500 10,160     -
   Baffi Robert EVP, Technical Operations   •       –      –    2013-05-14 4 AS $70.00 $1,400,000 D/D (20,000) 50,262     -
   Baffi Robert EVP, Technical Operations   •       –      –    2013-05-14 4 OE $21.51 $430,200 D/D 20,000 70,262     -
   Davis George Eric SVP, General Counsel   •       –      –    2013-05-14 4 S $70.34 $1,406,800 D/D (20,000) 41,708     -
   Davis George Eric SVP, General Counsel   •       –      –    2013-05-14 4 OE $21.51 $430,200 D/D 20,000 61,708     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-14 4 S $70.74 $1,773,551 I/I (25,000) 20,609     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-14 4 OE $12.99 $324,750 I/I 25,000 45,609     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2013-05-13 4 AS $69.26 $86,431 D/D (1,248) 7,270     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-13 4 AS $69.11 $552,896 I/I (8,000) 20,609     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-13 4 OE $12.99 $103,920 I/I 8,000 28,609     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-13 4 AS $68.12 $479,720 D/D (7,000) 88,101     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-13 4 GA $0.00 $0 I/I 7,064 20,609     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-13 4 GD $0.00 $0 D/D 7,064 90,101     -
   Davis George Eric SVP, General Counsel   •       –      –    2013-05-13 4 S $69.29 $179,452 D/D (2,590) 41,708     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-12 4/A D $67.68 $591,659 D/D (8,742) 102,165     -
   Wood Mark VP, Human Resources   •       –      –    2013-05-12 4 D $67.68 $152,821 D/D (2,258) 20,277     -
   Mueller Brian VP, Corporate Controller   •       –      –    2013-05-12 4 D $67.68 $55,295 D/D (817) 8,107     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-05-12 4 D $67.68 $203,108 D/D (3,001) 39,373     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2013-05-12 4 D $67.68 $50,895 D/D (752) 8,518     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-12 4 D $67.68 $600,525 D/D (8,873) 102,165     -
   Davis George Eric SVP, General Counsel   •       –      –    2013-05-12 4 D $67.68 $74,177 D/D (1,096) 44,298     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-10 4 AS $67.48 $53,985 D/D (800) 111,038     -

  1303 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 10 of 53
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed